Innovent Biologics’ New Drug Application for Advanced Renal Cell Carcinoma Accepted in China

Innovent Biologics ( (HK:1801) ) just unveiled an update.

Innovent Biologics announced that China’s National Medical Products Administration has accepted the New Drug Application for the combination of sintilimab and fruquintinib to treat advanced renal cell carcinoma. This development marks a significant step for Innovent in addressing unmet medical needs in China, further solidifying its position in the immuno-oncology sector and enhancing the clinical value of its product, TYVYT®.

The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.

More about Innovent Biologics

Innovent Biologics, Inc. is a biotechnology company focused on developing and commercializing high-quality biopharmaceuticals. The company specializes in immuno-oncology therapies and has a strong market presence in China, with its flagship product, TYVYT® (sintilimab injection), being a cornerstone in immuno-oncology treatment.

Average Trading Volume: 21,613,430

Technical Sentiment Signal: Buy

Current Market Cap: HK$104.1B

See more data about 1801 stock on TipRanks’ Stock Analysis page.